One of the largest radiopharma companies in the world is acquiring global rights to a pair of novel therapeutic and diagnostic drugs used to target a peptide receptor overexpressed in prostate and breast cancers.
Radiology practice leaders have a new way to assure their patients, communities, referrers and payers—and their own people—that the AI products they use are in compliance with safety and efficacy guidelines set by the American College of Radiology.
"This article will serve as a landmark reference for navigating short-term labor challenges in radiology," explains one editorial about the suggestions.
Six months after CMS effectively suspended its Appropriate Use Criteria program, some radiologists are planning to carry AUC principles forward anyway.
It’s one thing to know that cancer disparities often correlate with deleterious social determinants of health (SDOH). It’s another to equip healthcare professionals for applying the connection to affected patient populations.
